- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Pasithea reports positive PK data for PAS-004 tablet formulation | 1 | Investing.com | ||
| Fr | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 102 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| Do | Pasithea meldet positive Zwischendaten für MEK-Inhibitor in Krebsstudie | 5 | Investing.com Deutsch | ||
| Do | Pasithea reports positive interim data for MEK inhibitor in cancer trial | 1 | Investing.com | ||
| Do | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 74 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| Di | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | - | SEC Filings | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11. | Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 68 | GlobeNewswire (Europe) | MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 04.11. | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 27.10. | Pasithea Therapeutics passt Vergütung für Führungskräfte an und vergibt Aktienoptionen | 1 | Investing.com Deutsch | ||
| 27.10. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 116 | GlobeNewswire (Europe) | MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 16.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 08.09. | Pasithea advances to second dose cohort in NF1 clinical trial | 4 | Investing.com | ||
| 08.09. | Pasithea: NF1-Studie erreicht nach positiver Sicherheitsprüfung die nächste Dosierungsstufe | 1 | Investing.com Deutsch | ||
| 08.09. | Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 141 | GlobeNewswire (Europe) | -- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 03.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 31.07. | Pasithea completes enrollment of first cohort in NF1 clinical trial | 7 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 0,994 | -0,93 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| GENPREX | 3,000 | -5,06 % | Genprex, Inc.: Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials | New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer
Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast... ► Artikel lesen | |
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| RAPPORT THERAPEUTICS | 27,250 | +1,49 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,290 Euro und damit -31,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.